Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

M. Boegemann; K. Fizazi; N. Shore; T. L. Tammela; A. Ulys; E. Vjaters; S. Polyakov; M. Jievaltas; M. Luz; B. Alekseev; I. Kuss; M. -A. Le Berre; O. Petrenciuc; A. Snapir; T. Sarapohja; M. R. Smith

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

M. Boegemann, K. Fizazi, N. Shore, T. L. Tammela, A. Ulys, E. Vjaters, S. Polyakov, M. Jievaltas, M. Luz, B. Alekseev, I. Kuss, M. -A. Le Berre, O. Petrenciuc, A. Snapir, T. Sarapohja, M. R. Smith

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	149
Pages (from-to)	225-225
Number of pages	1
Journal	Oncology Research and Treatment
Volume	43
Issue number	SUPPL 4
Publication status	Published - Oct 2020
Event	Annual conference of the German, Austrian and Swiss Societies for Hematology and Medical oncology - virtual Duration: 9 Oct 2020 → 11 Oct 2020

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this

Boegemann, M., Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M. -A., Petrenciuc, O., Snapir, A., Sarapohja, T., & Smith, M. R. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). Oncology Research and Treatment, 43(SUPPL 4), 225-225. [149].

Boegemann, M. ; Fizazi, K. ; Shore, N. ; Tammela, T. L. ; Ulys, A. ; Vjaters, E. ; Polyakov, S. ; Jievaltas, M. ; Luz, M. ; Alekseev, B. ; Kuss, I. ; Le Berre, M. -A. ; Petrenciuc, O. ; Snapir, A. ; Sarapohja, T. ; Smith, M. R. / Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). In: Oncology Research and Treatment. 2020 ; Vol. 43, No. SUPPL 4. pp. 225-225.

@article{398242a565d9439bbce3bbffdda08409,

title = "Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)",

author = "M. Boegemann and K. Fizazi and N. Shore and Tammela, {T. L.} and A. Ulys and E. Vjaters and S. Polyakov and M. Jievaltas and M. Luz and B. Alekseev and I. Kuss and {Le Berre}, {M. -A.} and O. Petrenciuc and A. Snapir and T. Sarapohja and Smith, {M. R.}",

year = "2020",

month = oct,

language = "English",

volume = "43",

pages = "225--225",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "SUPPL 4",

note = "Annual conference<br/>of the German, Austrian and Swiss Societies for Hematology and<br/>Medical oncology ; Conference date: 09-10-2020 Through 11-10-2020",

}

Boegemann, M, Fizazi, K, Shore, N, Tammela, TL, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, B, Kuss, I, Le Berre, M-A, Petrenciuc, O, Snapir, A, Sarapohja, T & Smith, MR 2020, 'Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)', Oncology Research and Treatment, vol. 43, no. SUPPL 4, 149, pp. 225-225.

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). / Boegemann, M.; Fizazi, K.; Shore, N.; Tammela, T. L.; Ulys, A.; Vjaters, E.; Polyakov, S.; Jievaltas, M.; Luz, M.; Alekseev, B.; Kuss, I.; Le Berre, M. -A.; Petrenciuc, O.; Snapir, A.; Sarapohja, T.; Smith, M. R.

In: Oncology Research and Treatment, Vol. 43, No. SUPPL 4, 149, 10.2020, p. 225-225.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

AU - Boegemann, M.

AU - Fizazi, K.

AU - Shore, N.

AU - Tammela, T. L.

AU - Ulys, A.

AU - Vjaters, E.

AU - Polyakov, S.

AU - Jievaltas, M.

AU - Luz, M.

AU - Alekseev, B.

AU - Kuss, I.

AU - Le Berre, M. -A.

AU - Petrenciuc, O.

AU - Snapir, A.

AU - Sarapohja, T.

AU - Smith, M. R.

PY - 2020/10

Y1 - 2020/10

UR - https://www-webofscience-com.db.rsu.lv/wos/woscc/full-record/WOS:000575955000507

M3 - Meeting Abstract

VL - 43

SP - 225

EP - 225

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - SUPPL 4

M1 - 149

T2 - Annual conference<br/>of the German, Austrian and Swiss Societies for Hematology and<br/>Medical oncology

Y2 - 9 October 2020 through 11 October 2020

ER -

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Field of Science*

Publication Type*

Other files and links

Cite this